{
    "2018-09-17": [
        [
            {
                "time": "2018-09-27",
                "original_text": "Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "EU Approval",
                        "Two-Drug Regimen",
                        "HIV"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2018-09-28",
                "original_text": "Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Raise Ratings",
                        "Teva",
                        "Ajovy",
                        "FDA Approval"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-01",
                "original_text": "How Pharmaceutical ETFs Have Performed in 2018",
                "features": {
                    "keywords": [
                        "Pharmaceutical ETFs",
                        "Performed",
                        "2018"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-10-02",
                "original_text": "Competition Dynamics for Ajovy—Teva’s Migraine Drug",
                "features": {
                    "keywords": [
                        "Competition Dynamics",
                        "Ajovy",
                        "Teva",
                        "Migraine Drug"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-10-03",
                "original_text": "Allergan Frown Lines Study Passes Test on Higher Botox Dose",
                "features": {
                    "keywords": [
                        "Allergan",
                        "Frown Lines",
                        "Botox",
                        "Higher Dose"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-04",
                "original_text": "Teva's (TEVA) Migraine Drug Ajovy Receives FDA Approval",
                "features": {
                    "keywords": [
                        "Teva",
                        "Ajovy",
                        "FDA Approval",
                        "Migraine Drug"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-05",
                "original_text": "These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018",
                "features": {
                    "keywords": [
                        "Pharmaceutical Stocks",
                        "S&P 500",
                        "Surpassed",
                        "2018"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-06",
                "original_text": "Teva stock surges 7% after FDA approves migraine medication",
                "features": {
                    "keywords": [
                        "Teva",
                        "stock surges",
                        "FDA",
                        "migraine medication"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}